Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Zhejiang University

Status and phase

Enrolling

Phase 2

Conditions

Myeloid Malignancy

Relapsed/Refractory Acute Myeloid Leukaemia

Treatments

Drug: Venetoclax

Drug: mitoxantrone hydrochloride liposome

Drug: Cytarabine

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT06434662

CSPC-DED-AML-K13

Details and patient eligibility

About

The goal of this study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, cytarabine and venetoclax (MAV) in the treatment of relapsed or refractory (R/R) AML. It will also tentatively explore the correlation between different biological characteristics and therapeutic efficacy. The main questions it aims to answer are:Dose the combination regimen of MAV enhanced the composite complete remission in R/R AML? Participants will receive laboratory tests of bone marrow and blood specimens at regular times after MAV treatment.

Full description

Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy with a poor prognosis. The "3+7" regimen, combining anthracyclines with cytarabine, remains the standard treatment for first line treatment. However, about 20% of patients will develop into primary refractory disease, and more than 50% of patients who achieved complete remission will eventually relapse. For patients with R/R AML, there is currently no established standard treatment. Combining the third drugs with "3+7" regimen is one of the clinical exploration directions.

The purpose of this prospective, single-center, single-arm, pahse II study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, cytarabine and venetoclax in the treatment of R/R AML. All participants will receive MAV treatment including 24 mg/m2 mitoxantrone hydrochloride liposome on day 1, 1.0 g/m2 q12h cytarabine on day 1,3,5 and 400 mg venetoclax on day 2-10 with a dose escalation on day 2-4. Each cycle consists of 4 weeks. A maximum of 2 cycles of therapy are planned.

Enrollment

34 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.
Age ≥18.
Clinically diagnosed relapsed/refractory AML, excluding acute promyelocytic leukemia.
1. Initial treatment patients who failed after 2 courses of treatment with standard regimen.
2. Bone marrow blasts≥5% after the first CR/CRi, or reappearance of blasts in the blood in at least 2 peripheral blood samples at least one week apart, or leukemia cell infiltration appeared in extramedullary without treatment.
3. First conversion from MRD negativity to MRD positivity without treatment.
Physical status score of Eastern Oncology Collaboration Group (ECOG) : 0-2.
Researchers determined that the patients could tolerate intensive chemotherapy.
Life expectancy > 3 months.
AST/ALT≤2.5 ULN (for subjects with hepatic infiltration≤5 ULN); Total bilirubin≤1.5 ULN (for subjects with hepatic infiltration≤3 ULN); Serum creatinine≤1.5 ULN.

Exclusion criteria

Previous anti-tumor therapy meets one of the following criteria:
1. Prior therapy with mitoxantrone or mitoxantrone liposome;
2. Prior therapy with doxorubicin or anthracyclines, and the cumulative dose of doxorubicin > 360 mg/m^2 (1 mg doxorubicin was equivalent to 2 mg daunorubicin or 0.5 mg idarubicin);
3. Have received other anti-tumor therapy (including chemotherapy, targeted therapy, hormone therapy, Chinese medicines with anti-tumor activity, except those that do not affect the efficacy of the study as determined by the investigator) or participated in other clinical trials and received clinical trial drugs within 4 weeks or 5 half-lives of the drug before the study;
Cardiovascular diseases, including but not limited to:
1. QTc interval >480 ms or long QTc syndrome in screening;
2. Complete left bundle branch block, 2 or 3 grade atrioventricular block;
3. Requiring treatment of serious and uncontrolled arrhythmia;
4. New York Heart Association（NYHA≥3;
5. Cardiac ejection fraction (EF) was less than 50%;
6. Myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other history of arrhythmia or clinically serious pericardial disease that requires treatment within the first 6 months of enrollment, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
Central nervous system leukemia;
Previous or current occurrence of other malignancies (in addition to non-melanoma basal cell carcinoma of the skin that is effectively controlled, breast/cervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment within the past five years).
Subjects are suffering from any other uncontrollable disease (including but not limited to: uncontrolled diabetes and hypertension, and advanced infection);
HIV infection.
HBsAg or HBcAb positive, with HBV-DNA≥1x10^3 copies/mL; or HCV-RNA≥1x10^3 copies/mL;
A history of immediate or delayed allergy to similar drug and excipients of the investigate drug.
Pregnant, lactating female or subjects who refuse to use effective contraception during the study.
With a history of severe neurological or psychiatric illness.
Not suitable for this study as decided by the investigator.